Alcon, Inc. Product Pipeline Analysis

SUMMARY

Alcon, Inc. Product Pipeline Analysis

Summary

This report is an insightful source for data, analysis and strategic insights into a Alcon, Inc.'s pipeline and investigational products. The report also provides details on clinical trials covering trial phase, description, investigator information, primary and secondary end-points and trial results for products in development.

Scope

• Details of development stage by sector and equipment type.
• Pipeline products grouped by therapy area, development stage and trial phase.
• Detailed information on clinical trials covering trial phase, description, investigator .nformation, primary and secondary end-points and trial results.
• Trial updates, trial start and end dates, patient numbers and the trials primary outcome measures, secondary outcome measures.
• Product updates covering estimated approval dates and estimated launch dates.
• Descriptions of novel technologies relating to pipeline products of the company.
• Patents and patent applications covered for the product.
• News updates on key events relating to the product and its development.

Reasons to buy

• A single source to fulfill competitor information relating to products in development.
• Identify pipeline products that are potential competitor to your product lines.
Understand a company's strategic position by accessing detailed independent intelligence on its product pipeline.
• Access clinical trial information to map trial results and plan targeted marketing activities.
• Take corrective measures on your own development programs and R&D initiatives based on regulatory events of competitor product pipelines.
• Identification of potential investment opportunities.
• Build up knowledge base for potential distribution and marketing partners.
• Helps avoid patent infringement.
• Timelines from concept to market lets you keep track of market potential build for a new product.
Assess a company's future growth by determining its pipeline depth, for probable acquisition opportunities.

TABLE OF CONTENTS

1 Table of Contents 3
1.1 List of Tables 8
1.2 List of Figures 9
2 Company Snapshot 10
2.1 Key Information 10
2.2 Company Overview 10
2.3 Financial Performance 10
3 Business Description 11
3.1 Business Overview 11
3.2 Alcon International 11
3.2.1 Overview 11
3.2.2 Financials 11
3.2.3 Market View 11
3.3 Alcon United States 11
3.3.1 Overview 11
3.3.2 Financials 11
3.3.3 Market View 11
3.4 Major Products and Services 12
3.4.1 Overview 12
4 History 14
5 Business Strategy 17
5.1 Mission Statement 17
5.2 Strategy 17
5.3 Corporate Social Responsibility 17
5.3.1 Overview 17
5.3.2 Specific CSR Initiatives 17
6 Value Chain Analysis 19
6.1 Manufacturing 19
6.1.1 In House Manufacturing 19
6.1.2 Outsourcing 20
6.2 Product Development 20
6.2.1 Regulatory Approvals 20
6.2.2 Clinical Trials 20
6.2.3 Research and Development 20
6.3 Sales and Marketing 21
6.3.1 Partnerships and Alliances 21
6.3.2 Licensing Agreements 21
7 Competitors 22
8 Share Holding Structure 23
9 Key Employees 24
10 Key Employee Biographies 25
11 Company Statement 29
12 Locations And Subsidiaries 32
12.1 Head Office 32
12.2 Other Locations & Subsidiaries 32
13 Recent Developments 34
13.1 Strategy And Business Planning 34
13.1.1 Apr 13, 2008: Alcon To Build New Pharmaceutical Manufacturing Plant In Singapore 34
13.1.2 Sep 10, 2007: Alcon To Expand Swiss Operations 34
13.2 Financial Announcements 35
13.2.1 Jul 23, 2008: Alcon Reports 2Q 2008 Results 35
13.2.2 Jun 20, 2008: Alcon Laboratories Spends $0.24 Million On Lobbying In Q1 2008 37
13.2.3 Jun 17, 2008: Alcon To Declare Q2 2008 Results 37
13.2.4 May 06, 2008: Alcon Approves Dividend 37
13.2.5 Apr 23, 2008: Alcon Declares Q1 2008 Results 37
13.2.6 Mar 28, 2008: Alcon To Declare Q1 2008 Results 39
13.2.7 Feb 06, 2008: Alcon Declares Q4 2007 Results 39
13.2.8 Oct 24, 2007: Alcon Declares Q3 2007 Results 41
13.2.9 Jul 25, 2007: Alcon Declares Q2 2007 Results 42
13.2.10 May 09, 2007: Alcon Approves Dividend 44
13.2.11 Apr 25, 2007: Alcon's Q1 Global Sales Up By 14.3% 44
13.2.12 Mar 26, 2007: Alcon Announces Q1 2007 Financial Release Date 45
13.2.13 Feb 07, 2007: Alcon Declares Q4 2006 Results 46
13.2.14 Oct 23, 2006: Alcon's Q3 Global Sales Up By 12.4% 47
13.2.15 Sep 18, 2006: Alcon Announces Q3 2006 Financial Release Date 49
13.2.16 Sep 08, 2006: Alcon Approves Repurchase Of 5 Million Additional Shares 49
13.2.17 Jul 24, 2006: Alcon's Q2 Global Sales Up 11.8% To $1,310.8 Million 49
13.2.18 Jun 19, 2006: Alcon Announces Q2 2006 Financial Release Date 52
13.2.19 May 02, 2006: Alcon Approves Dividend 52
13.3 Corporate Communications 52
13.3.1 May 06, 2008: Alcon Announces Board Changes 52
13.3.2 Mar 10, 2008: Alcon Announces Management Changes 52
13.3.3 Sep 10, 2007: Alcon Senior Vice President To Retire 53
13.3.4 Jul 16, 2007: Alcon Appoints New CFO 53
13.3.5 Jun 26, 2007: Alcon CFO To Leave 53
13.3.6 May 09, 2007: Alcon Elects Board Members 53
13.3.7 May 02, 2006: Alcon Elects Board Members 53
13.4 Legal and Regulatory 54
13.4.1 Jun 26, 2007: Bausch & Lomb Files Suit Against Alcon 54
13.4.2 Jul 10, 2006: AMO Announces Patent Infringement Settlement With Alcon 54
13.5 Government and Public Interest 54
13.5.1 Jun 10, 2008: FDA Panel Recommends Stricter Contact Lens Labeling 54
13.6 Product News 55
13.6.1 Jun 25, 2008: Alcon Enters Into Patent Cross-Licensing Agreement With AMO 55
13.6.2 Feb 01, 2007: Alcon's AcrySof ReSTOR Apodized Diffractive Aspheric Intraocular Lens approved by FDA 56
13.6.3 Feb 01, 2007: Alcon's AcrySof ReSTOR Apodized Diffractive Aspheric Intraocular Lens Approved By FDA 56
13.6.4 Dec 18, 2006: Alcon Recalls 'Systane Free' Eye Drops 56
13.6.5 Dec 15, 2006: (ACL) Announces Voluntary Recall Of Systane(R) Free LIQUID GEL Lubricant Eye Drops In The United States, Including Puerto Rico. 56
13.6.6 Oct 25, 2006: Children's Hospital of Austin is Helping Save Young Patients' Eyesight with New Technology. 56
13.6.7 Jun 02, 2006: Alcon gets U.S. FDA approval for Ladar6000 Excimer Laser, Wavefront-Guided Hyperopia. 57
13.6.8 May 21, 2006: AcrySof IQ IOL Designated as a New Technology Intraocular Lens 57
13.6.9 Oct 12, 2005: FDA Approves Alcon's OPTI-FREE RepleniSH MPDS 57
13.6.10 Jan 15, 2005: Combination system provides extra protection. 57
13.6.11 Mar 01, 2004: Surgeons laud various advantages of viscoelastic duo. 57
13.6.12 Apr 14, 2003: Alcon Introduces INFINITI Vision System, a Revolutionary Cataract Removal System 57
13.6.13 Feb 28, 2003: What's Coming in 2003 58
13.6.14 Oct 24, 2002: Alcon Reports Third Quarter Operating Results 58
13.7 Product Approvals 58
13.7.1 Feb 01, 2007: Alcon's AcrySof ReSTOR Apodized Diffractive Aspheric Intraocular Lens approved by FDA 58
13.7.2 Feb 01, 2007: Alcon's AcrySof ReSTOR Apodized Diffractive Aspheric Intraocular Lens Approved By FDA 58
13.7.3 Oct 12, 2005: FDA Approves Alcon's OPTI-FREE RepleniSH MPDS 59
14 Alcon, Inc. Pipeline Products 60
14.1 Alcon, Inc. Product Pipeline Analysis 60
14.1.1 Alcon, Inc. Pipeline Products By Equipment Type 60
14.1.2 Alcon, Inc. Pipeline Products By Development Stage 61
14.1.3 Alcon, Inc. Pipeline Products By Therapy Area 62
14.1.4 Alcon, Inc. Pipeline Products By Clinical Trials 62
14.2 AcrySof ReSTOR IOL +3.0 Add 62
14.2.1 Product Description 62
14.2.2 Product Status 63
14.3 AcrySof Low Power ReSTOR lens 63
14.3.1 Product Description 63
14.3.2 Product Status 63
14.4 AcrySof thin-profile IOL 63
14.4.1 Product Description 64
14.4.2 Product Status 64
14.5 AcrySof ReSTOR Toric IOL 64
14.5.1 Product Description 64
14.5.2 Product Status 65
14.6 AcrySof Angle-supported Phakic Lens 65
14.6.1 Product Description 65
14.6.2 Product Status 65
14.6.3 Clinical Trials 66
14.7 New CONSTELLATION Vitreoretinal System 67
14.7.1 Product Description 67
14.7.2 Product Status 67
15 Appendix 68
15.1 Methodology 68
15.1.1 Coverage 68
15.1.2 Secondary Research 69
15.1.3 Primary Research 69
15.1.4 Expert Panel Validation 70
15.2 Contact Us 70
15.3 About Global Markets Direct 70
15.4 Disclaimer 70

1.1 List of Tables
Table 1: Alcon, Inc.,Key Facts, 2007 10
Table 2: Alcon, Inc., Share Holding Structure 23
Table 3: Alcon, Inc., Key Employees, 2007 24
Table 4: Alcon, Inc., Other Locations 32
Table 5: Alcon, Inc. Pipeline Products by Equipment Type 60
Table 6: Alcon, Inc. Pipeline Products By Development Stage 61
Table 7: Alcon, Inc. Pipeline Products By Therapy Area 62
Table 8: Alcon, Inc. Pipeline Products By Clinical Trials 62

1.2 List of Figures
Figure 1: Alcon, Inc., Value Chain Analysis 19
Figure 2: Alcon, Inc. Pipeline Products By Development Stage 61
Figure 3: Global Markets Direct Methodology 68